Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales

MT Newswires Live

2024/12/20

Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.

"Securing access to Pedmarqsi is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.

Price: 5.89, Change: +0.05, Percent Change: +0.86

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492428481"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492428481\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492428481?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492428481","market":"us","top_or_hot":-1,"title":"Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales","media":"MT Newswires Live","content":"<html><body><p> Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.</p><p>\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.</p><p>Price: 5.89, Change: +0.05, Percent Change: +0.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-12-20 23:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.</p><p>\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.</p><p>Price: 5.89, Change: +0.05, Percent Change: +0.86</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FENC","symbol_name":"Fennec Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492428481","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492428481","pubTimestamp":1734710251,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fennec Pharmaceuticals  said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.Price: 5.89, Change: +0.05, Percent Change: +0.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FENC":"Fennec Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"Fennec Pharmaceuticals的儿童听力损失药物在英格兰和威尔士获得研究所的认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FENC":0.9},"content_text":"Fennec Pharmaceuticals (FENC) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.\"Securing access to Pedmarqsi  is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment,\" Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.Price: 5.89, Change: +0.05, Percent Change: +0.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}